Advanced BioDesign is a French biotechnology company developing an innovative targeted therapy to treat resistant cancers, with a first indication in acute myeloid leukemia (AML).
Advanced BioDesign is focused on the development of novel anticancer drugs, focusing specifically on targeting ALDH as therapeutic approach for acute myeloid leukaemia and other cancers with high unmet medical needs.
Advanced BioDesign was founded in 2010 and is headquartered in Saint-Priest, Rhône-Alpes, France.
Advanced BioDesign's innovative strategy aims to overcome tumour chemoresistance and to restore or activate endogenous cell death mechanisms in cancer cells.
Advanced BioDesign's lead drug candidate, ABD-3001, is a small-molecule inhibitor of the ALDH family of enzymes that is at the initial stage of clinical development for a wide range of cancers, including acute myeloid leukaemia, non-small cell lung cancer, melanoma and others.
Advanced BioDesign is backed by Xerys Funds. The company raised an additional €9M ($9.8M) in a latest financing on Feb 25, 2020. This brings Advanced BioDesign's total funding to $17.9M to date.